SavedAdd your journal

Journals / Retina-Vitreus / 2022 / Cilt: 31 - Sayı: 1

Outcomes of Dexamethasone Implant Treatment in Patients with Diabetic Macula Edema Anatomically Unresponsive to Intravitreal Bevacizumab Treatment: Early Switch to Dexamethasone Study

Gökhan Demir
Abdullah Özkaya
Fatih Çoban
Ümit Çallı
Uğur Tunç
Pages
39–43
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Overall, 27 eyes of 24 patients were included in our study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the anatomical and visual outcomes of switching to intravitreal dexamethasone implant (IVD) in patients with diabetic macula edema unresponsive to 3 monthly consecutive intravitreal bevacizumab (IVB).
📊
Key Findings & Data:Methods: This retrospective study included patients with diabetic macular edema (DME) who showed anatomically poor response to 3 consecutive IVB injections and were switched to IVD treatment in early period.
💡
Conclusion & Impact:Results: Overall, 27 eyes of 24 patients were included in our study.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the anatomical and visual outcomes of switching to intravitreal dexamethasone implant (IVD) in patients with diabetic macula edema unresponsive to 3 monthly consecutive intravitreal bevacizumab (IVB). Methods: This retrospective study included patients with diabetic macular edema (DME) who showed anatomically poor response to 3 consecutive IVB injections and were switched to IVD treatment in early period. In the study population best-corrected visual acuity (BCVA), and central retinal thickness (CRT) were recorded at baseline, and on months 3, 6, 9, and 12. Results: Overall, 27 eyes of 24 patients were included in our study. The mean age was 61.5 ± 9.5 years. The mean BCVA at baseline was 0.70 ± 0.21 LogMAR while the mean BCVA after 3 consecutive IVB injections was 0.69 ± 0.19 LogMAR. (p:0.83). The mean BCVA was 0.52 ± 0.21 LogMAR, 0.39 ± 0.22 LogMAR and 0.45 ± 0.27 LogMAR at 6, 9 and 12 months, respectively. (p=0.013, p=0.002, p

🔖

Cite This Article

Demir, G., Özkaya, A., Çoban, F., Çallı, Ü., Tunç, U. (2022). Outcomes of Dexamethasone Implant Treatment in Patients with Diabetic Macula Edema Anatomically Unresponsive to Intravitreal Bevacizumab Treatment: Early Switch to Dexamethasone Study. Retina-Vitreus, Cilt: 31 - Sayı: 1, 39–43. https://ajindex.com/articles/588998

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jusufbegovic D, Mugavin MO, Schaal S. Evolution of Controlling Diabetic Retinopathy: Changing Trends in the Management of Diabetic Macular Edema at a Single Institution Over the Past Decade. Retina. 2015;35:929-34
  2. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no
  3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27:265-72
  4. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73-9
  5. Wang J, Xu X, Elliott MH, et al. Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes. 2010;59:2297-305
  6. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796-806
  7. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005
  8. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289-96
  9. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015;122:2044- 52
  10. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013-22
  11. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078-86.e2
  12. Eraslan S, Yıldırım Ö, Dursun Ö, et al. Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy. Turk J Ophthalmol. 2020;50:163-8
  13. Ozkaya A, Demir G, Kirmaci A. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment. Eur J Ophthalmol. 2020;30:363-9
  14. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Reti